X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AX-158 is a first in class oral Nck blocker, which is being evaluated in phase 2 clinical trials for the treatment of mild to moderate plaque psoriasis.
Lead Product(s): AX-158
Therapeutic Area: Dermatology Product Name: AX-158
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
AX-158 is a first-in-class, oral small molecule for the treatment of autoimmune diseases and selectively modulates, or adjusts, T Cell responses that play a critical role in immune system function. By selectively inhibiting Nck, a protein.
Lead Product(s): AX-158
Therapeutic Area: Dermatology Product Name: AX-158
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
AX-158 is a first-in-class, oral small molecule for the treatment of autoimmune diseases and selectively modulates, or adjusts, T Cell responses that play a critical role in immune system function. By selectively inhibiting Nck, a protein.
Lead Product(s): AX-158
Therapeutic Area: Immunology Product Name: AX-158
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
Artax will use these funds to support the clinical development of AX-158 in autoimmune diseases, including the addition of key clinical development personnel. AX-158 has the potential to treat T Cell-mediated diseases without the risk of immunosuppression.
Lead Product(s): AX-158
Therapeutic Area: Immunology Product Name: AX-158
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 11, 2022
Details:
In preclinical studies, AX-158 decreased key cytokines including INFγ, TNFα and IL-2. Based on this activity, Artax is planning future clinical development in autoimmune diseases, T cell malignancies and other related T cell pathologies.
Lead Product(s): AX-158
Therapeutic Area: Immunology Product Name: AX-158
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2021
Details:
U.S. Patent covers AX-158, certain additional backup compounds, and pharmaceutical compositions thereof, and is expected to expire no earlier than 2039 in the United States.
Lead Product(s): AX-158
Therapeutic Area: Immunology Product Name: AX-158
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
Artax Biopharma is poised to enter clinical trials with the small molecule AX- 158, a novel approach to treat multiple autoimmune diseases without causing the immunosuppression commonly associated with current autoimmune disease therapies.
Lead Product(s): AX-158
Therapeutic Area: Immunology Product Name: AX-158
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Details:
Proceeds from the financing will be used to support activities for a planned Q4 2020 filing of a Clinical Trial Application (CTA) with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for AX-158.
Lead Product(s): AX-158
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Columbus Venture Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series B Financing June 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
